343 related articles for article (PubMed ID: 28851294)
21. Combinations of Histone Deacetylase Inhibitors with Distinct Latency Reversing Agents Variably Affect HIV Reactivation and Susceptibility to NK Cell-Mediated Killing of T Cells That Exit Viral Latency.
Covino DA; Desimio MG; Doria M
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206330
[TBL] [Abstract][Full Text] [Related]
22. New Latency Reversing Agents for HIV-1 Cure: Insights from Nonhuman Primate Models.
Bricker KM; Chahroudi A; Mavigner M
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452425
[TBL] [Abstract][Full Text] [Related]
23. Getting the "Kill" into "Shock and Kill": Strategies to Eliminate Latent HIV.
Kim Y; Anderson JL; Lewin SR
Cell Host Microbe; 2018 Jan; 23(1):14-26. PubMed ID: 29324227
[TBL] [Abstract][Full Text] [Related]
24. The HIV Latency Reversal Agent HODHBt Enhances NK Cell Effector and Memory-Like Functions by Increasing Interleukin-15-Mediated STAT Activation.
Macedo AB; Levinger C; Nguyen BN; Richard J; Gupta M; Cruz CRY; Finzi A; Chiappinelli KB; Crandall KA; Bosque A
J Virol; 2022 Aug; 96(15):e0037222. PubMed ID: 35867565
[TBL] [Abstract][Full Text] [Related]
25. Activation of Latent HIV-1 T Cell Reservoirs with a Combination of Innate Immune and Epigenetic Regulators.
Palermo E; Acchioni C; Di Carlo D; Zevini A; Muscolini M; Ferrari M; Castiello L; Virtuoso S; Borsetti A; Antonelli G; Turriziani O; Sgarbanti M; Hiscott J
J Virol; 2019 Nov; 93(21):. PubMed ID: 31413127
[TBL] [Abstract][Full Text] [Related]
26. Therapeutics for HIV-1 reactivation from latency.
Sgarbanti M; Battistini A
Curr Opin Virol; 2013 Aug; 3(4):394-401. PubMed ID: 23810462
[TBL] [Abstract][Full Text] [Related]
27. Block-And-Lock: New Horizons for a Cure for HIV-1.
Moranguinho I; Valente ST
Viruses; 2020 Dec; 12(12):. PubMed ID: 33334019
[TBL] [Abstract][Full Text] [Related]
28.
Rosás-Umbert M; Ruiz-Riol M; Fernández MA; Marszalek M; Coll P; Manzardo C; Cedeño S; Miró JM; Clotet B; Hanke T; Moltó J; Mothe B; Brander C;
Front Immunol; 2020; 11():418. PubMed ID: 32265913
[TBL] [Abstract][Full Text] [Related]
29. Maraviroc reactivates HIV with potency similar to that of other latency reversing drugs without inducing toxicity in CD8 T cells.
López-Huertas MR; Jiménez-Tormo L; Madrid-Elena N; Gutiérrez C; Vivancos MJ; Luna L; Moreno S
Biochem Pharmacol; 2020 Dec; 182():114231. PubMed ID: 32979351
[TBL] [Abstract][Full Text] [Related]
30. In vivo activation of latent HIV with a synthetic bryostatin analog effects both latent cell "kick" and "kill" in strategy for virus eradication.
Marsden MD; Loy BA; Wu X; Ramirez CM; Schrier AJ; Murray D; Shimizu A; Ryckbosch SM; Near KE; Chun TW; Wender PA; Zack JA
PLoS Pathog; 2017 Sep; 13(9):e1006575. PubMed ID: 28934369
[TBL] [Abstract][Full Text] [Related]
31. Potent
Bardhi A; Wu Y; Chen W; Li W; Zhu Z; Zheng JH; Wong H; Jeng E; Jones J; Ochsenbauer C; Kappes JC; Dimitrov DS; Ying T; Goldstein H
J Virol; 2017 Oct; 91(20):. PubMed ID: 28794022
[TBL] [Abstract][Full Text] [Related]
32. Eradication of HIV-1 latent reservoirs through therapeutic vaccination.
Pankrac J; Klein K; Mann JFS
AIDS Res Ther; 2017 Sep; 14(1):45. PubMed ID: 28893280
[TBL] [Abstract][Full Text] [Related]
33. HIV-1 Eradication: Early Trials (and Tribulations).
Spivak AM; Planelles V
Trends Mol Med; 2016 Jan; 22(1):10-27. PubMed ID: 26691297
[TBL] [Abstract][Full Text] [Related]
34. The development of immune-modulating compounds to disrupt HIV latency.
Remoli AL; Marsili G; Battistini A; Sgarbanti M
Cytokine Growth Factor Rev; 2012; 23(4-5):159-72. PubMed ID: 22766356
[TBL] [Abstract][Full Text] [Related]
35. Alternate NF-κB-Independent Signaling Reactivation of Latent HIV-1 Provirus.
Acchioni C; Remoli AL; Marsili G; Acchioni M; Nardolillo I; Orsatti R; Farcomeni S; Palermo E; Perrotti E; Barreca ML; Sabatini S; Sandini S; Parolin C; Lin R; Borsetti A; Hiscott J; Sgarbanti M
J Virol; 2019 Sep; 93(18):. PubMed ID: 31243131
[TBL] [Abstract][Full Text] [Related]
36. Block and Lock HIV Cure Strategies to Control the Latent Reservoir.
Ahlenstiel CL; Symonds G; Kent SJ; Kelleher AD
Front Cell Infect Microbiol; 2020; 10():424. PubMed ID: 32923412
[TBL] [Abstract][Full Text] [Related]
37. Reversal of Latency as Part of a Cure for HIV-1.
Rasmussen TA; Tolstrup M; Søgaard OS
Trends Microbiol; 2016 Feb; 24(2):90-97. PubMed ID: 26690612
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic vaccination following early antiretroviral therapy elicits highly functional T cell responses against conserved HIV-1 regions.
Kopycinski J; Yang H; Hancock G; Pace M; Kim E; Frater J; Stöhr W; Hanke T; Fidler S; Dorrell L;
Sci Rep; 2023 Oct; 13(1):17155. PubMed ID: 37821472
[TBL] [Abstract][Full Text] [Related]
39. A setback for kick and kill?
Tobin SC
AIDS; 2019 Apr; 33(5):N6. PubMed ID: 30649048
[No Abstract] [Full Text] [Related]
40. The role of latency reversal agents in the cure of HIV: A review of current data.
Bashiri K; Rezaei N; Nasi M; Cossarizza A
Immunol Lett; 2018 Apr; 196():135-139. PubMed ID: 29427743
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
